Receptor tyrosine kinase inhibitors in cancer

被引:48
|
作者
Ebrahimi, Nasim [1 ]
Fardi, Elmira [2 ]
Ghaderi, Hajarossadat [3 ]
Palizdar, Sahar [4 ]
Khorram, Roya [5 ]
Vafadar, Reza [6 ]
Ghanaatian, Masoud [7 ]
Rezaei-Tazangi, Fatemeh [8 ]
Baziyar, Payam [9 ]
Ahmadi, Amirhossein [10 ]
Hamblin, Michael R. [11 ]
Aref, Amir Reza [12 ,13 ]
机构
[1] Univ Isfahan, Fac Sci & Technol, Dept Cell & Mol Biol & Microbiol, Genet Div, Esfahan, Iran
[2] Islamic Azad Univ Tehran, Med Branch, Tehran, Iran
[3] Pasteur Inst Iran, Lab Regenerat & Med Innovat, Tehran, Iran
[4] Islamic Azad Univ Tehran East Branch, Fac Basic Sci, Div Microbiol, Tehran, Iran
[5] Shiraz Univ Med Sci, Bone & Joint Dis Res Ctr, Dept Orthoped Surg, Shiraz, Iran
[6] Kerman Univ Med Sci, Dept Orthopead Surg, Kerman, Iran
[7] Univ Toulouse III Paul Sabatier, Master Bio Sante Parcours Toulouse Grad Sch Canc A, Toulouse, France
[8] Fasa Univ Med Sci, Sch Med, Dept Anat, Fasa, Iran
[9] Univ Mazandaran, Fac Basic Sci, Dept Mol & Cell Biol, Babolsar, Iran
[10] Persian Gulf Univ, Fac Nano & Bio Sci & Technol, Dept Biol Sci & Technol, Bushehr 75169, Iran
[11] Univ Johannesburg, Fac Hlth Sci, Laser Res Ctr, ZA-2028 Doornfontein, South Africa
[12] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[13] Xsphera Biosci, Translat Med Grp, 6 Tide St, Boston, MA 02210 USA
基金
美国国家卫生研究院;
关键词
Targeted therapy; Immune therapy; RTK inhibitors; Drug resistance; Cancer therapy; RENAL-CELL CARCINOMA; GROWTH-FACTOR; LUNG-CANCER; THERAPEUTIC TARGET; DRUG-RESISTANCE; PHASE-III; HEPATOCELLULAR-CARCINOMA; ONCOGENIC ACTIVATION; ACQUIRED-RESISTANCE; MOLECULAR TARGET;
D O I
10.1007/s00018-023-04729-4
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Targeted therapy is a new cancer treatment approach, involving drugs that particularly target specific proteins in cancer cells, such as receptor tyrosine kinases (RTKs) which are involved in promoting growth and proliferation, Therefore inhibiting these proteins could impede cancer progression. An understanding of RTKs and the relevant signaling cascades, has enabled the development of many targeted drug therapies employing RTK inhibitors (RTKIs) some of which have entered clinical application. Here we discuss RTK structures, activation mechanisms and functions. Moreover, we cover the potential effects of combination drug therapy (including chemotherapy or immunotherapy agents with one RTKI or multiple RTKIs) especially for drug resistant cancers.
引用
收藏
页数:18
相关论文
共 50 条
  • [1] Receptor tyrosine kinase inhibitors in cancer
    Nasim Ebrahimi
    Elmira Fardi
    Hajarossadat Ghaderi
    Sahar Palizdar
    Roya Khorram
    Reza Vafadar
    Masoud Ghanaatian
    Fatemeh Rezaei-Tazangi
    Payam Baziyar
    Amirhossein Ahmadi
    Michael R. Hamblin
    Amir Reza Aref
    Cellular and Molecular Life Sciences, 2023, 80
  • [2] Resistance to receptor tyrosine kinase inhibition in cancer: molecular mechanisms and therapeutic strategies
    Alexander, Peter B.
    Wang, Xiao-Fan
    FRONTIERS OF MEDICINE, 2015, 9 (02) : 134 - 138
  • [3] Nanomedicine of tyrosine kinase inhibitors
    Smidova, Veronika
    Michalek, Petr
    Goliasova, Zita
    Eckschlager, Tomas
    Hodek, Petr
    Adam, Vojtech
    Heger, Zbynek
    THERANOSTICS, 2021, 11 (04): : 1546 - 1567
  • [4] Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer
    Kujtan, Lara
    Subramanian, Janakiraman
    EXPERT REVIEW OF ANTICANCER THERAPY, 2019, 19 (07) : 547 - 559
  • [5] Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy
    Qin, Shuang
    Li, Anping
    Yi, Ming
    Yu, Shengnan
    Zhang, Mingsheng
    Wu, Kongming
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2019, 12 (1)
  • [6] The Next Generation of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in the Treatment of Lung Cancer
    Steuer, Conor E.
    Khuri, Fadlo R.
    Ramalingam, Suresh S.
    CANCER, 2015, 121 (08) : E1 - E6
  • [7] Focus on resistance to tyrosine kinase inhibitors in renal cancer
    Falkowski, Sabrina
    BULLETIN DU CANCER, 2018, 105 : S255 - S260
  • [8] Estrogen Receptor β Is Involved in Acquired Resistance to EGFR-tyrosine Kinase Inhibitors in Lung Cancer
    Sugiura, Hiroki
    Miki, Yasuhiro
    Iwabuchi, Erina
    Saito, Ryoko
    Ono, Katsuhiko
    Sato, Ikuro
    Okada, Yoshinori
    Sasano, Hironobu
    ANTICANCER RESEARCH, 2021, 41 (05) : 2371 - 2381
  • [9] Recent updates on the resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors and resistance reversion strategies in lung cancer
    Tripathi, Surya K.
    Pandey, Kamal
    Rengasamy, Kannan R. R.
    Biswal, Bijesh K.
    MEDICINAL RESEARCH REVIEWS, 2020, 40 (06) : 2132 - 2176
  • [10] ALDH-positive lung cancer stem cells confer resistance to epidermal growth factor receptor tyrosine kinase inhibitors
    Huang, Cheng-Po
    Tsai, Meng-Feng
    Chang, Tzu-Hua
    Tang, Wei-Chien
    Chen, Su-Yu
    Lai, Hsiao-Hsuan
    Lin, Ting-Yu
    Yang, James Chih-Hsin
    Yang, Pan-Chyr
    Shih, Jin-Yuan
    Lin, Shwu-Bin
    CANCER LETTERS, 2013, 328 (01) : 144 - 151